Clinical Trial ProgressThe initiation of the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis comes on schedule, aligning with prior guidance.
Efficacy And SafetyDescartes-08 has generated compelling open-label Phase 2a and placebo-controlled Phase 2b results, showing deep and durable efficacy with patients.
Financial PositionCartesian ended 1Q25 with $182.1M in cash and equivalents which the company is guiding as sufficient to fund operations through completion of the Phase 3 AURORA trial and into mid-2027.